Anticoagulation medications show no gender-based variations in outcomes for TAVR patients

May 06, 2016

Orlando, Fla. - A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality. The BRAVO 3 results were presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions in Orlando, Fla.

BRAVO 3 assessed contemporary TAVR procedures administered through the leg, or transfemoral procedures, and compared the use of two anticoagulation medications, bivalirudin and unfractionated heparin (UFH). The study was a randomized multicenter trial with 31 centers participating (n = 802). The primary endpoint was major bleeding occurring within 48 hours. Major bleeding was defined as Bleeding Academic Research Consortium (BARC) type 3b, which is overt bleeding with a significant drop in hemoglobin or that requires surgical intervention and/or IV vasoactive agents to control.

"Prior evidence has shown that while women have a higher rate of survival post TAVR, they are at a greater risk of complications from bleeding soon after a procedure," said Anita W. Asgar, MD, the paper's lead author. "BRAVO 3 was designed to look at whether different anticoagulation medications could reduce the early risk in women."

The study was comprised of 49 percent women (n = 391, 195 received bivalirudin and 196 received UFH) and 51 percent men (n = 411, 209 received bivalirudin and 202 received UFH). Women were older than men and had fewer comorbidities, such as coronary artery disease, atrial fibrillation and diabetes. While women had a lower EuroSCORE I-- a predictor of operative mortality in patients undergoing cardiac surgery-- all patients were considered high-risk for TAVR.

Compared with men, at 30 days, women demonstrated similar survival (19 men vs. 19 women, p = 0.87), major adverse cardiac event (34 men vs. 29 women, p = 0.65) and vascular complications (32 men vs. 43 women, p = 0.12).

"The good news is that we found early outcomes for women were comparable to those of men," said Dr. Asgar. "That being said, the BRAVO 3 study only looked at outcomes over 30 days, so the next step would be to see long-term results for post-TAVR procedures."

BRAVO 3 did find a trend -- although not statistically significant -- that women who were given bivalirudin experienced less mortality. Dr. Asgar noted this indication could warrant further studies, with a larger population, on using bivalirudin over UFH for women.
Dr. Asgar reported no disclosures.

Dr. Asgar presented "Sex-Based Differences in Outcomes with Bivalirudin or Unfractionated Heparin for Transcatheter Aortic Valve Replacement: Results from the BRAVO 3 Randomized Trial" on Friday, May 6, 2016 at 9:45 a.m. ET.

For more information about the SCAI 2016 Scientific Sessions, visit

About SCAI

The Society for Cardiovascular Angiography and Interventions is a 4,500-member professional organization representing invasive and interventional cardiologists in approximately 70 nations. SCAI's mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's public education program, Seconds Count, offers comprehensive information about cardiovascular disease. For more information about SCAI and Seconds Count, visit or Follow @SCAI on Twitter for the latest heart health news.

Society for Cardiovascular Angiography and Interventions

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to